Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine.

ABSTRACT:

Objective

To examine changes in the occurrence, severity, and symptoms of headache episodes in patients with chronic migraine following eptinezumab treatment.

Methods

PROMISE-2 was a double-blind, placebo-controlled, parallel-group trial that randomized adults with chronic migraine to eptinezumab 100 mg, 300 mg, or placebo IV every 12 weeks for up to 24 weeks (2 infusions). Headache episodes (migraine and non-migraine) and their characteristics were reported in daily electronic diaries during the 28-day baseline and throughout the 24-week treatment period.

Results

A total of 1072 patients were included in this post hoc analysis. Mean monthly headache days decreased by 8.9 (100 mg) and 9.7 (300 mg) compared to a 7.3 decrease in placebo over the first 4-week interval po

SUBMITTER: McAllister P 

PROVIDER: S-EPMC9445399 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature